Brickell Biotech, Inc.
(NASDAQ : BBI)

( )
BBI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.53%170.200.7%$964.07m
ABBVAbbVie, Inc. 1.67%140.341.9%$841.79m
PFEPfizer Inc. 0.61%49.570.9%$830.12m
LLYEli Lilly & Co. 0.39%302.501.1%$749.11m
MRKMerck & Co., Inc. 1.24%88.490.7%$749.03m
BMYBristol-Myers Squibb Co. 2.33%73.801.0%$664.96m
SIGASIGA Technologies, Inc. -4.76%22.190.0%$393.19m
AZNAstraZeneca Plc -1.38%65.121.0%$376.21m
ALNYAlnylam Pharmaceuticals, Inc. 5.56%230.748.1%$254.69m
GSKGSK Plc -0.64%40.310.3%$216.46m
HZNPHorizon Therapeutics Plc 0.07%69.655.4%$197.93m
SGENSeagen Inc. 1.43%178.335.7%$191.45m
NVSNovartis AG 0.43%85.940.2%$174.13m
RGENRepligen Corp. 1.70%250.466.7%$158.40m
NVONovo Nordisk A/S -0.76%102.420.1%$151.74m

Company Profile

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.